Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...

TransCode Therapeutics shares are trading lower by 16% during Monday's session. The company announced a 1-for-33 reverse ...

As previously announced, the 1-for-33 reverse stock split will automatically convert thirty-three current shares of TransCode’s common stock into one new share of common stock. No fractional shares ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BOSTON - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), an RNA oncology-focused clinical-stage company, has been granted conditional continued listing on The Nasdaq Stock Market.

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today positive results with its lead ...

Read Also: ‘Pharma Bro’ Martin Shkreli Tells Investors To ‘Short SAVA,’ Stock Falls Over 80% After Phase 3 Update According to data from Benzinga Pro, RNAZ has a 52-week high of $18.48 and ...

BOSTON - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), an RNA oncology company, announced today that its Phase 1 clinical trial will progress to the second cohort of patients. This ...

BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to ...

This page features the latest news about the Transcode Therapeutics ... of Cohort 1 Safety Data TransCode Therapeutics, Inc. (RNAZ), the RNA oncology company committed to more effectively treating ...